Lupus

The study highlighted the potential role of shared decision-making in building trust in physicians among patients with SLE.

Results from a Mendelian randomization analysis indicate type 1 diabetes significantly increases the likelihood of autoimmune conditions like rheumatoid arthritis and multiple sclerosis.

Amanda Mixon, PA-C, discusses how rheumatic diseases may first present in skin, ocular or gastric symptoms.

Two patients with autoimmune diseases from 2 phase ½ RESET trials had complete B cell depletion within 15 days post-infusion with CABA-201 and needed no additional medication.

A recent study provides some evidence of the ability to potentially reduce belimumab dose in a subset of patients with SLE.

Karen Costenbader, MD, discusses the 2 post hoc analyses that demonstrated treatment with belimumab reduces flares and increases response rates among patients with early active SLE.

Karen Costenbader, MD, discusses how early intervention with belimumab in patients with lupus significantly reduces disease flares and prevents irreversible organ damage.

A propensity score matched analysis suggests use of SGLT2 inhibitors could reduce risk of negative outcomes in patients with systemic lupus erythematosus and type 2 diabetes.

Data presented at NKF Spring Clinical Meeting suggest events including myocardial infarction and stroke are more prevalent among patients with lupus in North America.

FDA approves label update for voclosporin (Lupkynis) in lupus nephritis, reflecting long-term AURORA data and new kidney function monitoring guidance.

Most (94%) anti-nucleocapsid positivity was linked to a self-reported COVID-19 infection within the prior 3 months.

Mohamed Cherry, MD, and Neil Kramer, MD, shed light on a phase 1 trial using CAR-T cell therapy for SLE and its potential implications for lupus treatment.

An analysis of data from more than 5 million people suggests rheumatic and immune-mediated diseases were associated with increased rates of childlessness and elevated risk of adverse pregnancy outcomes.

A groundbreaking phase 1 study using CAR-T cells to treat severe lupus highlights a collaborative effort between the Cellular Therapy Program and rheumatology programs to pioneer innovative patient care.

The Xist ribonucleoprotein (RNP) complex, linked to the XX sex chromosome complement, influences the susceptibility to autoimmunity.

The percentage of lymphocyte apoptosis in peripheral blood was significantly higher in patients with jSLE when compared with healthy controls.

A retrospective cohort analysis suggests the monoclonal antibody may help patients with SLE reduce their reliance on oral corticosteroids over 1 year after initiating treatment.

The progression toward more targeted, disease-modifying options for the historically difficult rheumatic disease made more headway in 2023.

Data from the phase 3 TULIP long-term extension trial support the favorable benefit-risk profile of anifrolumab-fnia demonstrated in previous trials.

Results provide the first clinical evidence to suggest that afimetoran may offer a benefit to patients with cutaneous lupus erythematosus.

Throughout 2023, interest in the application of CAR-T and other cell therapies to autoimmune disease skyrocketed, with a multitude of clinical trials being initiated by various companies.

Expert rheumatologists discuss current treatment options for lupus nephritis and emerging therapies with newer mechanisms of action.

This new late-breaking data presented at ACR 2023 was the first clinical evidence indicating efficacy of afimetoran for those with CLE.

In this research presented at ACR 2023, a connection between antiphospholipid antibodies and a greater potential risk of cardiovascular disease was identified.

This research into improving quality measures for lupus patients was presented at ACR 2023 and funded by the CDC.